Author Archives: admin001

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) ...

BriaCell’s Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly ...

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer

The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s ...

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. ...

BriaCell Therapeutics Announces Closing of Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Therapeutics Announces Pricing of Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS(TM)

Lung metastasis (from metastatic breast cancer) resolved – after only 2 months (4 doses) of ...

BriaCell Announces Completion of 15:1 Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...